Compare WTI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTI | NGNE |
|---|---|---|
| Founded | 1983 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.5M | 327.8M |
| IPO Year | 2004 | 2014 |
| Metric | WTI | NGNE |
|---|---|---|
| Price | $3.46 | $22.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $60.13 |
| AVG Volume (30 Days) | ★ 5.8M | 157.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.40% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $487,096,000.00 | $925,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.73 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.09 | $6.88 |
| 52 Week High | $3.82 | $37.27 |
| Indicator | WTI | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 67.13 | 56.11 |
| Support Level | $1.71 | $19.44 |
| Resistance Level | N/A | $25.79 |
| Average True Range (ATR) | 0.30 | 2.28 |
| MACD | 0.02 | 0.24 |
| Stochastic Oscillator | 72.34 | 51.91 |
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.